Pipeline
SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs being evaluated as standalone and combination therapies. Our development programs include two potentially registrational clinical trials in rare tumor types as well as several other programs addressing highly prevalent, genetically defined cancers. Our team is working with urgency on behalf of the underserved patients living with these devastating illnesses.
Program
Indication
- Preclinical
- Phase 1
- Phase 2
- Phase 3
phase
Partner/ Collaborator
Relapsed/ Refractory Multiple Myeloma
PHASE 1B
Ph1

Relapsed/ Refractory Multiple Myeloma
PHASE 1 PLANNED
Ph1

Relapsed/ Refractory Multiple Myeloma
PHASE 1B/2 PLANNED
Ph1

Relapsed/ Refractory Multiple Myeloma
PHASE 1 PLANNED
Ph1

* Being developed by MapKure, LLC, or MapKure, an entity jointly owned by SpringWorks and BeiGene.